Artificial blood vessel loaded with human amniotic mesenchymal stem cells as well as preparation method and application of artificial blood vessel
By loading human amniotic mesenchymal stem cells in small-diameter artificial blood vessels and using PLCL electrospinning technology, the problem of low thrombosis and patency rates is solved, and higher vascular patency rates and tissue repair effects are achieved, improving clinical application value.
Patent Information
- Application Number
- CN202410945867.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-08
AI Technical Summary
The existing small-diameter artificial blood vessels face the problems of thrombosis and low long-term patency in terms of hemodynamic characteristics, which is difficult to meet clinical needs, and autologous vascular acquisition is highly invasive and not suitable for all patients.
Using novel artificial blood vessels loaded with human amniotic mesenchymal stem cells, tubular structures were prepared by electrospinning of polylactic acid-polycaprolactone copolymer PLCL, and hAMSC cells were uniformly planted in their lumen, optimizing porosity and fibrous structure to promote cells Grow and adhesion to improve histocompatibility and regenerative potential.
It has achieved the improvement of patency rate and therapeutic effectiveness of artificial blood vessels, reduced postoperative complications, promoted vascular repair and regeneration, and enhanced the clinical application value and success rate.
Smart Images

Figure CN118903560A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical engineering technology, specifically relates to tissue engineering, regenerative medicine, small-caliber artificial blood vessels and other technologies, especially a new artificial blood vessel loaded with human amniotic mesenchymal stem cells and its preparation method and use. Background Art
[0002] Cardiovascular disease is one of the leading causes of death worldwide, particularly in China, where the disease affects 330 million people. Cardiovascular disease accounts for over 44% of all deaths in both urban and rural areas. The prevention and treatment of cardiovascular disease is crucial for alleviating both medical and social burdens. Vascular transplantation is a key treatment option for end-stage, severe obstructive cardiovascular disease, with autologous vascular transplantation considered the gold standard due to its excellent compatibility and long-term patency.
[0003] Although autologous vascular transplantation has significant advantages, its invasive acquisition method causes great damage to patients and may cause complications. In addition, due to individual differences among patients, approximately one-third of patients have difficulty obtaining suitable autologous blood vessels. The large-caliber artificial blood vessels already on the market have achieved satisfactory results in the replacement of large blood vessels such as the aorta. However, small-caliber artificial blood vessels (SDVG) face the challenges of thrombosis and low long-term patency due to their special hemodynamic characteristics, making it difficult to meet clinical needs.
[0004] To improve the patency of SDVGs, scientists have developed a variety of artificial blood vessels with antithrombotic properties. Key strategies include modifying the material with anticoagulant compounds to mitigate thrombosis or introducing a cell lining with antithrombotic properties. While chemical modification strategies suffer from degradation over time, cell lining strategies exhibit enhanced antithrombotic properties due to the self-renewal and paracrine functions of living cells.
[0005] In exploring cell resources for the anti-thrombotic modification of SDVG, human amniotic mesenchymal stem cells (hAMSCs) have shown potential as a next-generation SDVG seed cell due to their multipotential differentiation capacity, lack of tumorigenicity, low immunogenicity, and excellent immune tolerance. Furthermore, novel scaffold materials, particularly electrospinning of biodegradable polymers, are considered the next generation of artificial vascular scaffold materials, promising to further improve the performance of artificial blood vessels and the success rate of clinical applications. Summary of the Invention
[0006] The purpose of the present invention is to provide a novel artificial blood vessel loaded with human amniotic mesenchymal stem cells, a preparation method thereof, and corresponding uses, so as to overcome the deficiencies of the prior art.
[0007] Based on the first main aspect of the present invention, an artificial blood vessel loaded with human amniotic mesenchymal stem cells is provided, which is prepared by electrospinning polylactic acid-polycaprolactone copolymer PLCL into a tubular structure, and the tubular structure has the following characteristics: 0.36±0.10μm, pore size of 3.63±1.66μm, wall thickness of 510±50μm, inner diameter of 2.19±0.05mm, and porosity of 69.74%±5.81%; and, loaded with human amniotic mesenchymal stem cells hAMSC.
[0008] This invention achieves a tubular scaffold with a specific porosity and fiber structure by precisely controlling the electrospinning process of polylactic acid-polycaprolactone copolymer (PLCL). This structure not only provides an excellent microenvironment for cell growth but also, through optimized pore size and wall thickness, provides ample space for cells to adhere and proliferate. Furthermore, the loading of human amniotic mesenchymal stem cells (hAMSCs) imparts improved tissue compatibility and the potential to promote angiogenesis, thereby enhancing the clinical value and therapeutic effectiveness of the artificial blood vessels.
[0009] In some embodiments, the human amniotic mesenchymal stem cells (hAMSCs) are extracted and identified by the following steps: mechanical stripping combined with two-enzyme digestion; flow cytometry analysis; Vimentin immunostaining; osteogenic differentiation ability test; adipogenic differentiation ability test.
[0010] The extraction and identification steps of hAMSCs ensure that the selected cells possess a high degree of purity and specific biological properties. Flow cytometry analysis and Vimentin immunostaining validate the phenotypic and mesenchymal characteristics of hAMSCs, while osteogenic and adipogenic differentiation assays confirm their multidirectional differentiation potential. These properties are crucial for the long-term function and successful integration of artificial blood vessels into host tissues, helping to improve their stability and promote tissue repair.
[0011] The mechanical stripping combined with two-enzyme digestion method first obtains amniotic tissue from the placenta, and then, under sterile conditions, uses surgical instruments such as forceps and scissors to carefully peel off the amnion and other tissue layers of the placenta to obtain pure amniotic tissue. This step needs to be performed under a microscope to ensure the integrity of the amnion and avoid contamination from other tissues. The stripped amniotic tissue is then cut into small pieces to increase the surface area of the tissue for subsequent enzymatic digestion. These small pieces are then further homogenized using a tissue homogenizer to form a cell suspension.
[0012] The two-enzyme digestion method involves adding appropriate amounts of two enzymes—typically collagenase and neutral protease—to the homogenized cell suspension. These enzymes break down the extracellular matrix and help release cells attached to it. The mixture is incubated at 37°C for a period of time to allow the enzymes to fully function. The digested cell suspension is filtered through a sterile filter to remove undigested tissue debris. The cell pellet is then centrifuged to remove enzymes and non-cellular components from the supernatant. The cell pellet is resuspended in an appropriate cell culture medium and seeded into cell culture plates or flasks. The cells are cultured at 37°C and 5% CO2 to promote cell attachment and proliferation. Once the cells reach a certain density, they are subcultured to obtain a sufficient number of hAMSCs for subsequent experiments and applications.
[0013] As a further preferred embodiment, the flow cytometry analysis is used to determine the phenotype of hAMSC, including the expression of CD markers; the Vimentin immunostaining is used to verify the mesenchymal characteristics of hAMSC; the osteogenic differentiation ability test comprises culturing hAMSC in an osteogenic induction medium containing sodium β-glycerophosphate, vitamin D3 and dehydrocholesterol, and observing the activity of alkaline phosphatase and the formation of mineralized nodules; the adipogenic differentiation ability test comprises culturing hAMSC in an adipogenic induction medium containing dexamethasone, insulin, indomethacin and isoproterenol, and observing the formation of oil droplets.
[0014] Using specific culture conditions and chemical induction media, the osteogenic and adipogenic differentiation abilities of hAMSCs were tested and demonstrated. This differentiation capacity is a key factor in evaluating the potential of hAMSCs for tissue engineering applications, as they can promote the structural and functional reconstruction of blood vessels and surrounding tissues. Furthermore, by observing alkaline phosphatase activity, the formation of mineralized nodules, and the formation of oil droplets, the differentiation status of hAMSCs can be accurately assessed, thus ensuring that the loaded cells possess the ability to promote tissue regeneration and repair.
[0015] As a further preferred embodiment, the extraction and identification further include determination of cell doubling time and cell survival rate, wherein the cell doubling time is determined by cell counting method, and the cell survival rate is determined by MTT or CCK-8 assay.
[0016] Determination of cell doubling time and cell viability provides important indicators for evaluating the biological activity and proliferation capacity of hAMSCs. The cell doubling time, determined by cell counting, reflects the rapid proliferation of hAMSCs, which is crucial for rapid cell coverage and long-term maintenance within the artificial blood vessel. Cell viability, measured by MTT or CCK-8 assays, ensures early survival of hAMSCs after implantation, providing a foundation for subsequent tissue integration and functional recovery. Comprehensive consideration of these indicators helps improve the clinical success rate and long-term effectiveness of artificial blood vessels.
[0017] Based on the second main aspect of the present invention, a method for preparing the aforementioned artificial blood vessel loaded with human amniotic mesenchymal stem cells is provided, the method comprising the following steps: using electrospinning technology to dissolve PLCL in a solvent to prepare an electrospinning solution, and processing the electrospinning solution into a tubular scaffold using an electrospinning device; freeze-drying the prepared tubular scaffold and sterilizing it with ultraviolet light; uniformly loading human amniotic mesenchymal stem cells hAMSC into the inner lumen of the tubular scaffold using a rotary implantation technique; and allowing the hAMSC to adhere to the wall and proliferate in the inner lumen of the tubular scaffold.
[0018] This preparation method provides a key step for the successful manufacture of artificial blood vessels, ensuring the consistency and reproducibility of the final product. Precisely controlling electrospinning technology to prepare the PLCL tubular scaffold not only enables precise regulation of the scaffold's microstructure, but also ensures the scaffold's biosafety through freeze-drying and ultraviolet sterilization. Furthermore, the application of rotational seeding technology enables the uniform distribution of hAMSCs within the scaffold lumen and their adherent proliferation, a process crucial for the formation of a functional vascular endothelium, thereby improving the in vivo compatibility of the artificial blood vessel and promoting rapid tissue integration.
[0019] In some embodiments, the concentration of the electrospinning solution is 10%, and the voltage used during the electrospinning process is controlled at 12-14 kV.
[0020] Controlling electrospinning solution concentration and voltage is crucial for producing high-quality artificial vascular tubular scaffolds. A 10% electrospinning solution concentration and a voltage range of 12-14 kV provide optimal conditions for achieving uniform fiber diameter and pore size, which are essential for cell adhesion, migration, and proliferation. Precise control of these parameters helps maintain the scaffold's mechanical properties and biocompatibility, ensuring enhanced stability and functionality for both in vitro and in vivo applications.
[0021] In some embodiments, the rotational implantation technique comprises the following steps: injecting a hAMSC cell suspension into a tubular scaffold; fixing both ends of the scaffold with a vascular clamp; allowing the scaffold to stand at 37°C and 5% CO2 for 2 hours; and flipping the scaffold 90° every 30 minutes for a total rotation of 360°.
[0022] Rotational seeding technology is a key step in achieving uniform distribution of hAMSCs within artificial blood vessels. By injecting a cell suspension into the tubular scaffold and securing it with a vascular clamp, combined with static and rotating conditions under specific conditions, this technique ensures sufficient contact between hAMSCs and the scaffold material, promoting uniform cell seeding and subsequent proliferation. This uniform cell distribution is crucial for forming a continuous endothelial layer and improving the anti-thrombotic ability of the artificial blood vessel.
[0023] In some embodiments, the freeze-drying step is performed at -80°C for 24 hours.
[0024] The freeze-drying step is crucial for ensuring the structural stability and cell viability of the artificial vascular scaffold. Freeze-drying at -80°C for 24 hours effectively removes moisture from the scaffold, reducing the risk of cell damage and maintaining the scaffold's porous structure, creating an ideal environment for cell seeding and growth. This step is crucial for maintaining the long-term stability and functionality of the artificial vascular scaffold.
[0025] In some embodiments, the processing of the electrospinning liquid into a tubular scaffold by an electrospinning device comprises the following steps: dissolving PLCL in hexafluoroisopropanol; performing electrospinning using a rotating stainless steel rod as a receiving device; and peeling the prepared blood vessel from the stainless steel rod and immersing the prepared blood vessel together with the spinning membrane in deionized water.
[0026] The final steps in the fabrication process, including dissolving PLCL in hexafluoroisopropanol, electrospinning using a rotating stainless steel rod, and peeling the resulting vessel from the rod and subsequent processing, collectively ensure the morphological and structural characteristics of the artificial blood vessel. In particular, this fabrication method produces a scaffold with appropriate pore size and porosity, providing the necessary microenvironment for cell adhesion, growth, and differentiation, thereby improving the overall performance and clinical application potential of the artificial blood vessel.
[0027] According to the third main aspect of the present invention, there is provided the use of an artificial blood vessel loaded with human amniotic mesenchymal stem cells in the preparation of an apparatus for treating cardiovascular diseases, including coronary artery disease, peripheral artery disease and aortic disease.
[0028] This application leverages the excellent cytocompatibility of artificial blood vessels and the multidirectional differentiation potential of hAMSCs, aiming to provide a new therapeutic approach to promote the repair and regeneration of damaged blood vessels. Through the implantation of hAMSCs, artificial blood vessels can not only improve vascular patency, but also promote the repair of surrounding tissues by secreting growth factors and extracellular matrix components, reducing postoperative complications and thus improving patient prognosis.
[0029] In addition to cardiovascular disease, this artificial blood vessel may also be used in other medical fields requiring vascular replacement or repair. For example, it could play a vital role in vascular reconstruction after tumor resection, repair of traumatic vascular damage, and vascular regeneration after complex fractures. Its unique structure and cell-carrying capacity can promote rapid vascularization of damaged areas, accelerate wound healing, and improve treatment success rates.
[0030] Given the immunomodulatory properties of hAMSCs, these artificial blood vessels also have the potential to be used in the treatment of autoimmune diseases. In these diseases, blood vessels are often invaded and damaged by inflammation. Leveraging the immunomodulatory function of hAMSCs can reduce inflammatory responses, protect blood vessels from further damage, and promote the repair of damaged vessels. Furthermore, hAMSCs' anti-inflammatory and angiogenesis-promoting abilities may also make them useful in the treatment of chronic wound healing and diabetic foot disease.
[0031] Small-caliber artificial blood vessels are a bottleneck in the treatment of cardiovascular diseases that urgently needs to be overcome. This paper proposes a novel artificial blood vessel solution using a preparation strategy based on stem cells and a biodegradable electrospun composite. This solution uses human AMSCs as seed cells, which have the advantages of high vitality, abundant content, and convenient extraction.
[0032] Furthermore, the PLCL electrospun material, used as a scaffold substrate, exhibits high biosafety and moderate mechanical properties. By seeding human Adenomatous mesenchymal stem cells (hAMSCs) within the PLCL electrospun tubular scaffold, an artificial blood vessel that met the design requirements was successfully fabricated, and its feasibility was verified in in vitro and in vivo experiments.
[0033] Experimental results demonstrate that the hAMSC-PLCL vascular graft possesses excellent mechanical properties, cytocompatibility, and in vitro hemocompatibility. It synergizes with VEGF to promote hAMSC-induced endothelial cell differentiation, making it suitable for vascular transplantation. Subcutaneous transplantation in rats demonstrates good tissue compatibility and confirms the hAMSC-PLCL vascular graft's ability to promote angiogenesis. In vivo hemocompatibility testing demonstrates its ability to resist acute thrombosis.
[0034] In further in vivo experiments, hAMSC-PLCL artificial blood vessels were implanted into a rat abdominal aorta replacement model. One month later, the results showed that the artificial blood vessels achieved a 100% patency rate, while the cell-free PLCL artificial blood vessels had only a 60% patency rate.
[0035] Histochemical and immunofluorescence staining analyses revealed that hAMSC loading enhanced the regenerative effects of the grafts, as evidenced by deeper cell infiltration, greater extracellular matrix deposition, and more complete intimal layer formation. This suggests that hAMSCs can enhance the patency and regenerative properties of grafts through multiple pathways. Overall, this study demonstrates the clinical potential of hAMSC-PLCL grafts. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, without paying any creative work, other drawings obtained based on these drawings still fall within the scope of the present invention.
[0037] Figure 1 Figure 1 shows the implantation of hAMSCs in the lumen of a PLCL artificial blood vessel in one embodiment of the present invention. In the figure: (A) hAMSCs implanted in the lumen of a PLCL artificial blood vessel; (B) The PLCL artificial blood vessel after being flipped 180 degrees.
[0038] Figure 2 Figure 3 shows DAPI staining of hAMSCs in a PLCL artificial blood vessel in one embodiment of the present invention (scale bar = 100 μm). In the figure: (A) DAPI staining of a cross section of a PLCL artificial blood vessel; (B) DAPI staining of the lumen of a PLCL artificial blood vessel.
[0039] Figure 3 The figure shows the HE staining results of one embodiment of the present invention. In the figure: (A) artificial blood vessel without hAMSCs; (B) artificial blood vessel with hAMSCs (scale bar = 50 μm).
[0040] Figure 4 The Masson staining results of one embodiment of the present invention are shown in the figure: (A) artificial blood vessel without hAMSCs; (B) artificial blood vessel with hAMSCs (scale bar = 50 μm).
[0041] Figure 5 The EVG staining results of one embodiment of the present invention are shown in the figure: (A) artificial blood vessel without hAMSCs; (B) artificial blood vessel with hAMSCs (scale bar = 50 μm).
[0042] Figure 6 The von-Kossa staining results of one embodiment of the present invention are shown in the figure: (A) artificial blood vessel without hAMSC seeding; (B) artificial blood vessel seeded with hAMSC (scale bar = 50 μm).
[0043] Figure 7 The results of Safranin O staining in one embodiment of the present invention are shown in the figure: (A) artificial blood vessel without hAMSCs; (B) artificial blood vessel with hAMSCs (scale bar = 50 μm).
[0044] Figure 8 Figure 2 shows the immunofluorescence staining results for EC markers in one embodiment of the present invention. Green fluorescence represents the corresponding target protein, and blue fluorescence represents the cell nucleus (scale bar = 100 μm). In the figure, (A), (C), and (E) respectively show immunofluorescence staining for CD31, vWF, and VE-Cadherin in PLCL vascular grafts without hASMC seeding; (B), (D), and (F) respectively show immunofluorescence staining for CD31, vWF, and VE-Cadherin in PLCL vascular grafts originally seeded with hAMSCs.
[0045] Figure 9 Figure 2 shows immunofluorescence staining results for SMC markers in one embodiment of the present invention. Green fluorescence represents the corresponding target protein, and blue fluorescence represents the cell nucleus (scale bar = 100 μm). (A) (C) (E) (G) show immunofluorescence staining of α-SMA, calponin, SM-MHC, and OPN in a PLCL vascular graft without hASMC implantation; (B) (D) (F) (H) show immunofluorescence staining of α-SMA, calponin, SM-MHC, and OPN in a PLCL vascular graft implanted with hAMSCs.
[0046] Figure 10 Figure 2 shows immunofluorescence staining results for macrophage markers in one embodiment of the present invention. Green fluorescence represents the corresponding target protein, and blue fluorescence represents the cell nucleus (scale bar = 100 μm). In the figure, (A), (C), and (E) respectively show immunofluorescence staining for CD68, iNOS, and CD206 in a PLCL vascular graft without hASMC seeding; (B), (D), and (H) respectively show immunofluorescence staining for CD68, iNOS, and CD206 in a PLCL vascular graft seeded with hAMSCs.
[0047] Figure 11 Figure 2 shows the immunofluorescence staining results of extracellular matrix markers in one embodiment of the present invention. Green fluorescence represents the corresponding target protein, and blue fluorescence represents the cell nucleus (scale bar = 100 μm). In the figure, (A) and (C) respectively show immunofluorescence staining of Collagen I and Collagen III in a PLCL vascular graft without hASMC implantation; (B) and (D) respectively show immunofluorescence staining of Collagen I and Collagen III in a PLCL vascular graft implanted with hASMC.
[0048] Figure 12 Figure 2 shows immunofluorescence staining results for a polyester polymer-specific degrading enzyme in one embodiment of the present invention. Green fluorescence represents the corresponding target protein, and blue fluorescence represents the cell nucleus (scale bar = 100 μm). In the figure, (A) and (C) show immunofluorescence staining for pancreatic lipase and endothelial lipase, respectively, in a PLCL graft without hASMC implantation; (B) and (D) show immunofluorescence staining for pancreatic lipase and endothelial lipase, respectively, in a PLCL graft implanted with hASMC.
[0049] Figure 13 Figure 1 shows immunofluorescence staining results for matrix metabolism enzymes in one embodiment of the present invention. Green fluorescence represents the corresponding target protein, and blue fluorescence represents the cell nucleus (scale bar = 100 μm). In the figure, (A), (C), (E), and (G) respectively show immunofluorescence staining for MMP2, MMP9, TIMP1, and TIMP2 in PLCL artificial blood vessels without hASMC implantation. (B), (D), (F), and (H) respectively show immunofluorescence staining for MMP2, MMP9, TIMP1, and TIMP2 in PLCL artificial blood vessels implanted with hAMSCs.
[0050] Figure 14 Figure 2 shows the results of human cell nuclear immunofluorescence staining in one embodiment of the present invention. Green fluorescence represents NUMA1, and blue fluorescence represents the cell nucleus (scale bar = 100 μm). In the figure, (A) and (B) respectively show NUMA1 immunofluorescence staining of a PLCL vascular graft without hASMC implantation and a PLCL vascular graft implanted with hAMSCs. DETAILED DESCRIPTION
[0051] The preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings so that the objects, features and advantages of the present invention can be more clearly understood. It should be understood that the embodiments shown in the accompanying drawings are not intended to limit the scope of the present invention, but are only intended to illustrate the essential spirit of the technical solution of the present invention.
[0052] In the following description, for the purpose of illustrating the various disclosed embodiments, certain specific details are set forth in order to provide a thorough understanding of the various disclosed embodiments. However, those skilled in the relevant art will recognize that the embodiments may be practiced without one or more of these specific details. In other cases, well-known devices, structures, and techniques associated with this application may not be shown or described in detail to avoid unnecessarily obscuring the description of the embodiments.
[0053] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any manner in one or more embodiments.
[0054] Example 1:
[0055] In this embodiment, the following English abbreviations may be involved. The following Table 1 shows the full English and Chinese names of these abbreviations.
[0056] Table 1: Chinese and English abbreviations
[0057]
[0058]
[0059] This embodiment is implemented according to the following steps:
[0060] 1PLCL tubular scaffold preparation and morphology analysis
[0061] 1.1 Preparation of PLCL tubular scaffolds
[0062] (1) Preparation of electrospinning solution
[0063] PLCL (ie, PLCL 50:50, average molecular weight 80,000 Da, supplier: Jinan Daigang) with a molar ratio of 50:50 was dissolved in hexafluoroisopropanol to prepare an electrospinning solution with a concentration of 10%.
[0064] (2) Preparation of PLCL tubular scaffolds by electrospinning
[0065] The prepared electrospinning solution was loaded into a syringe, inverted to remove air bubbles, and then secured to a syringe pump. During the electrospinning process, a rotating stainless steel rod with a diameter of 2 mm and a rotation speed of 500 rpm served as a receiving device to produce the artificial blood vessel. The entire spinning process lasted for 6 hours, with the receiving distance maintained at 15 cm. The flow rate was set at 1 mL / h, and the voltage was controlled between 12 and 14 kV.
[0066] (3) Material post-processing
[0067] After spinning, the prepared blood vessels were peeled from the stainless steel rod and immersed in a small amount of deionized water along with the spinning membrane. They were then frozen at -80°C for 24 hours and dried overnight in a freeze dryer. Prior to use, the material was sterilized by UV irradiation and soaked in 75% alcohol for 1 hour. The material was then soaked in 0.1% gelatin solution in a 37°C incubator for 60 minutes to promote cell adhesion to the scaffold surface.
[0068] 1.2 Key morphology analysis of PLCL tubular stent
[0069] The microstructure of the artificial blood vessel was analyzed by SEM images. The SEM sample preparation process was as follows: freeze-dry the sample, spray-coat it with gold for 60 seconds, and observe it under SEM at a scanning voltage of 10kV.
[0070] (1) Fiber diameter of PLCL artificial blood vessels
[0071] The average diameter of the PLCL artificial blood vessels was measured in SEM images. 100 fibers were manually measured and analyzed using ImageJ software.
[0072] (2) Pore diameter of PLCL artificial blood vessel
[0073] The pore diameter (pd) of the PLCL artificial blood vessel was measured using SEM images. ImageJ software was used to manually circle 50 representative pores formed by the fibers in the same plane and fit them to approximate circles. The pore diameter was defined as the diameter of the circle.
[0074] (3) Wall thickness and inner diameter measurement
[0075] Fit the graft tightly together. Use a digital gage to measure the distance between the two opposing surfaces of the graft to determine the total thickness. Divide the total thickness by 2 to determine the graft's wall thickness. Use a vernier caliper to measure the graft's outer diameter and subtract the wall thickness from this value to determine the inner diameter.
[0076] (4) Porosity measurement
[0077] The dried graft was weighed and then immersed in 100% ethanol for 2 h. After removal, the graft was gently wiped to remove excess ethanol and weighed again.
[0078] The porosity of the artificial blood vessel was calculated using the following equation:
[0079] V eth =(W wet -W dry ) / D eth
[0080] V PLCL =W dry / D PLCL
[0081] Scaffold porosity=V eth / (V PLCL +V eth )×100%
[0082] in:
[0083] Wdry W: dry weight of artificial blood vessel; wet : wet weight of artificial blood vessel; V eth : Volume of ethanol trapped in the artificial blood vessel; V PLCL : volume of artificial blood vessel; D PLCL :PLCL density (1.2g / cm 3 );D eth : Density of 100% ethanol (0.789 g / cm 3 ).
[0084] 2PLCL tubular scaffold seeded with hAMSCs
[0085] 2.1 PLCL tubular stent preparation
[0086] Soak a 1-cm artificial blood vessel in 75% alcohol and sterilize it under UV irradiation for 1 hour. Wash it three times with PBS. Soak it in 0.1% gelatin solution in a 37°C incubator for 60 minutes, then remove any excess gelatin by aspiration.
[0087] 2.2 Cell seeding
[0088] Take hAMSC, digest, centrifuge, resuspend, dilute 5 times and count to ensure the concentration is 1×106 cells / 20μL. Inject 20μL of cell suspension into the artificial blood vessel and fix both ends with vascular clamps. Place the artificial blood vessel in the well plate and soak it with culture medium (such as Figure 1 Use tweezers throughout the entire process to avoid contamination.
[0089] 2.3 Cell culture
[0090] Place the seeded scaffold in a 37°C, 5% CO2 incubator for 2 hours to allow cells to adhere. Flip the scaffold 90° every 30 minutes, for a total of 360°, to ensure uniform cell seeding. After 2 hours, remove the vascular clamp and continue standard culture for 1 day to complete the seeding process.
[0091] Analysis of structural parameters of 3hAMSC-PLCL artificial blood vessels
[0092] This example successfully fabricated a PLCL vascular prosthesis using electrospinning technology, using PLCL as the spinning solution, by optimizing electrospinning conditions. The prepared PLCL vascular prosthesis was subsequently characterized in detail. Scanning electron microscopy (SEM) observations of the PLCL vascular prosthesis surface revealed a random and uniform distribution of material fibers, demonstrating excellent fiber structural characteristics.
[0093] Measurements using a digital micrometer thickness gauge and vernier caliper revealed a wall thickness of 510 ± 50 μm and an inner diameter of 2.19 ± 0.05 mm. ImageJ software was used to analyze the fiber diameter and pore size of the artificial blood vessels (Table 2), and the porosity was measured using the liquid immersion method.
[0094] The results showed that the fiber diameter of the PLCL artificial blood vessel was 0.36±0.10μm, the pore size was 3.63±1.66μm, and the porosity was 69.74%±5.81%. This porosity level is sufficient to promote nutrient exchange and cell infiltration, thereby ensuring the long-term patency of the graft and optimizing its biological performance.
[0095] Table 2: Key morphological characteristics of PLCL artificial blood vessels
[0096]
[0097]
[0098] Analysis of cell attachment of 4hAMSC-PLCL artificial blood vessels
[0099] The present invention uses a rotational implantation method to load hAMSCs into the PLCL artificial blood vessel. By optimizing the conditions for cell rotational implantation, better cell adhesion can be achieved. After one day, the attachment of hAMSCs to the inner wall of the PLCL artificial blood vessel was observed by DAPI staining.
[0100] The fluorescence results of the cross section showed that the blue fluorescence emitted by the nucleus of hAMSCs was densely surrounded by the lumen of the artificial blood vessel, which indicated that the implanted hAMSCs were attached to the inner wall of the PLCL artificial blood vessel more evenly (e.g. Figure 2 After unfolding the vessel's inner wall, blue cell nuclei were evenly and extensively distributed throughout the vessel lumen, demonstrating the successful preparation of a hAMSC-loaded PLCL electrospun artificial blood vessel. This result also demonstrates that hAMSCs adhere well to the material surface, laying the foundation for their growth and further functionalization on the artificial scaffold.
[0101] hAMSCs are a stem cell resource for tissue engineering. Their unique placental origin offers distinct advantages over commonly used MSCs, such as BM-MSCs, including widespread availability, non-invasiveness, no ethical barriers, high purity, ease of extraction, and high viability. Despite their widespread application in regenerative medicine and cell therapy, their use in SDVG has not been reported. PLCL electrospun tubular scaffolds are an excellent substrate for artificial blood vessels. The combination of hAMSCs and PLCL electrospun fabrication may offer a novel artificial vascular design, combining the advantages of both approaches.
[0102] The invention extracted human amniotic membrane stem cells (hAMSCs) from amniotic membrane tissue and demonstrated that the extracted hAMSCs met the requirements of subsequent experiments through a series of characterizations, including flow cytometry, vimentin immunostaining, and osteogenic and adipogenic differentiation. Furthermore, the invention successfully utilized electrospinning technology to produce a PLCL50:50 tubular scaffold with the desired implant length, inner diameter, fiber diameter, porosity, pore size, and wall thickness. After uniformly loading the hAMSCs within the tubular scaffold lumen using an optimized rotary implantation technique, the invention successfully produced the SDVGs required for subsequent experiments.
[0103] The in vitro performance evaluation of artificial blood vessels is an important step in testing whether they can enter the in vivo evaluation stage. By testing the key mechanical properties of hAMSC-PLCL artificial blood vessels, the present invention confirms that it meets the requirements for implantation in the rat abdominal aorta replacement model. The good proliferation ability and low cytotoxicity of hAMSC on the PLCL electrospinning substrate demonstrate the good cell compatibility of hAMSC-PLCL artificial blood vessels. In the blood compatibility test, the present invention found that hAMSC-PLCL artificial blood vessels do not cause an abnormal increase in thrombin activity, do not promote hemolysis, and do not promote platelet adhesion and activation, and have good blood compatibility. In addition, the present invention also found that the PLCL electrospinning substrate can synergistically promote the ability of VEGF to induce hAMSC to differentiate into EC. In summary, these evaluations show that hAMSC-PLCL artificial blood vessels meet the requirements for in vivo implantation and have the potential for in vivo application.
[0104] Evaluation of histocompatibility of 5hAMSC-PLCL artificial blood vessels
[0105] To further evaluate the safety of the hAMSC-PLCL vascular graft, the present invention evaluated its tissue compatibility by subcutaneously implanting the PLCL graft in rats. These evaluations provide a detailed understanding of the PLCL graft's impact on surrounding tissues in vivo, determining whether it can successfully integrate with host tissues without triggering adverse immune responses.
[0106] 5.1 Analysis of HE staining results
[0107] After 2 weeks of subcutaneous implantation, the implanted artificial blood vessels were harvested. Figure 3 As shown in the figure, HE staining results show that compared with the cell-free group, the implantation of hAMSCs leads to more and deeper cell infiltration and extracellular matrix distribution of PLCL electrospun artificial blood vessels, while only a small amount of extracellular matrix is visible inside the cell-free PLCL electrospun scaffold. Both scaffolds containing and not containing hAMSCs are well integrated with the tissue, and no obvious inflammatory response and immune rejection are observed, indicating that the hAMSC-PLCL artificial blood vessels have good tissue compatibility.
[0108] 5.2 Analysis of Masson staining results
[0109] According to the results of Masson staining, Figure 4 As shown, the hAMSC-treated artificial blood vessels have a large number of red muscle fibers on their outer surface, and some blue collagen can be seen inside the artificial blood vessels, extending deep into the vessels. In contrast, only a small amount of muscle fibers and collagen can be seen on and inside the artificial blood vessels without hAMSC implantation. Collagen fibers primarily provide structural support in blood vessels, enhancing their mechanical strength and elasticity. In artificial blood vessels, collagen fibers can mimic the outer structure of natural blood vessels, which helps them integrate with surrounding tissues and improve their stability and durability. Myofibroblasts are responsible for regulating the contraction and relaxation of blood vessels, controlling blood flow and blood pressure. This shows that the implantation of hAMSCs promotes the production of extracellular matrix, including muscle fibers and collagen fibers.
[0110] 5.3 Analysis of EVG staining results
[0111] like Figure 5 As shown, EVG staining of the artificial blood vessels revealed that only a small amount of black elastic fibers and almost no red collagen fibers were observed on the exterior of the artificial blood vessels without hAMSC implantation. In contrast, after implantation with hAMSCs, a greater number of elastic and collagen fibers were observed. Elastic fibers provide blood vessels with the necessary elasticity and resilience, enabling them to adapt to blood flow fluctuations and pressure changes. They are a crucial component of the vascular extracellular matrix. Significantly, hAMSC implantation significantly increased the deposition of elastic fibers.
[0112] 5.4 Analysis of von-Kossa staining results
[0113] like Figure 6 As shown in the figure, no black calcium salt deposits were observed in the artificial blood vessels of the two groups 14 days after subcutaneous implantation, indicating that no calcification occurred in the artificial blood vessels. Vascular calcification often occurs in diseases such as arteriosclerosis, diabetes, chronic kidney disease and hypertension.
[54] , it can affect the elasticity of blood vessels, make blood vessels harder, and reduce the ability of blood vessels to adapt to changes in blood flow pressure, thereby increasing the risk of cardiovascular disease.
[0114] 5.5 Analysis of Safranin O staining results
[0115] like Figure 7 As shown, Safranin O staining of the artificial blood vessels revealed that 14 days after implantation, more and more uniform red mucopolysaccharides were observed in the artificial blood vessels seeded with hAMSCs, suggesting that the introduction of hAMSCs resulted in greater deposition of mucopolysaccharide extracellular matrix in the artificial blood vessels. Mucopolysaccharides are one of the main components of the extracellular matrix, helping to maintain the structural integrity and elasticity of tissues.
[0116] In vivo blood compatibility analysis of 6hAMSC-PLCL artificial blood vessels
[0117] The researchers then conducted an in vivo blood compatibility analysis on the hAMSC-PLCL artificial blood vessels to further assess their safety. Two hours after implantation in a rat abdominal aorta replacement model, the artificial blood vessels were harvested and observed for weight changes, thrombus formation, and platelet adhesion before and after implantation.
[0118] 6.1 Weight comparison before and after implantation
[0119] The artificial blood vessel was weighed before and after sampling, and the weight difference before and after was calculated to obtain the weight of the adsorbent of the artificial blood vessel, most of which was the weight of the thrombus. The size of the blood clot formed after circulating in the body for 2 hours was estimated from this.
[0120] Before and after the experiment, the average mass of the adsorbate in the acellular PLCL artificial blood vessel was 13.43 mg, while the average mass of the adsorbate in the hAMSC-loaded PLCL artificial blood vessel group, i.e., the PLCL (hAMSC) group, was 7.53 mg. Loading hAMSC reduced the average mass of the adsorbate by 5.9 mg.
[0121] The present invention uses t-test to perform statistical analysis on the two groups of data, and the result shows that the P value is 0.077, which is very close to 0.05. In order to further visually observe whether there is thrombosis, the present invention further analyzes whether there is thrombosis in the lumen by taking pictures.
[0122] 6.2 Direct observation under microscope
[0123] The resulting artificial blood vessels were photographed, and the longitudinal section showed that some thrombus formation was observed on the PLCL artificial blood vessels without hAMSC implantation, while the amount of thrombus adhered to the artificial blood vessels implanted with hAMSCs was less (the same was true for cross-sectional observations).
[0124] 6.3SEM observation
[0125] The present inventors subsequently used SEM to observe the surface of the artificial blood vessels. Within the lumen of the PLCL artificial blood vessels without hAMSC implantation, a large number of protein aggregates, a small number of red blood cells, and a small number of activated platelets were observed. In contrast, only a small number of platelets were found on the lumen surface of the PLCL artificial blood vessels implanted with hAMSCs, and these platelets were in an inactivated state. The experimental results showed that the acellular PLCL artificial blood vessels caused a small amount of platelet activation during the acute implantation phase, but the hAMSC loading inhibited platelet activation, thereby inhibiting thrombosis. The study showed that MSCs can reduce platelet adhesion through the heparan sulfate proteoglycans expressed on their surface.
[0126] Analysis of patency of 7hAMSC-PLCL artificial blood vessels in vivo
[0127] The present invention further implanted the artificial blood vessels into the abdominal aorta replacement model of SD rats and observed their patency rate one month later. Five PLCL artificial blood vessels, both containing and without cells, were implanted into the abdominal aorta of SD rats. This experiment not only simulated the physiological conditions that artificial blood vessels might face in vivo but also provided important data on the effectiveness and safety of the present invention in practical applications.
[0128] One rat in the acellular PLCL artificial blood vessel group died 8 and 14 days after implantation. Autopsies revealed thrombotic occlusion in these two artificial blood vessels. The remaining three rats were still alive and well when the samples were harvested one month later, and their blood vessels were found to be unobstructed after the samples were harvested. All rats in the hAMSC-loaded PLCL artificial blood vessel group were alive and well when the samples were harvested one month later, and their blood vessels were also found to be unobstructed after the samples were harvested. Statistics on the patency rates of the PLCL and PLCL(hAMSC) artificial blood vessels showed that all hAMSC-PLCL artificial blood vessels were patent, achieving a 100% patency rate, while only three of the five PLCL artificial blood vessels were patent, with a patency rate of only 60%. The data show that the introduction of hAMSCs effectively improves the patency rate of PLCL electrospun artificial blood vessels.
[0129] In vivo remodeling analysis of 8hAMSC-PLCL artificial blood vessels
[0130] 8.1 Analysis of Histochemical Staining Results after Abdominal Aorta Transplantation
[0131] In order to observe the remodeling of artificial blood vessels and explore the effect of hAMSC introduction on vascular remodeling, the present invention observed the tissue remodeling of artificial blood vessels in rats through chemical staining such as HE, EVG, von-Kossa, and Safranin O.
[0132] HE staining showed that compared with acellular PLCL artificial blood vessels, hAMSC-PLCL artificial blood vessels had deeper and denser cell infiltration and extracellular matrix expression in the vessel wall. The inner layer of the vessel wall formed an intimal layer with more cells and richer extracellular matrix, and the hAMSC-PLCL was closer to natural blood vessels. In addition, no obvious excessive infiltration of inflammatory cells was observed in either group of artificial blood vessels, indicating good tissue compatibility of the artificial blood vessels. However, there are still certain differences in structure compared to natural blood vessels. The present invention believes that the main reason is related to the shorter implantation time in vivo.
[0133] EVG staining showed that almost no brown elastic fibers could be observed inside and outside the artificial blood vessels without hAMSC implantation, and only some red collagen fibers were visible. After implantation of hAMSCs, a large amount of brown elastic fibers and some collagen fibers were observed in the present invention.
[0134] 30 days after implantation in the abdominal aorta, no black calcium salt deposits were observed in the artificial blood vessels of both groups, indicating that no calcification occurred during the vascular remodeling process.
[0135] Safranin O staining of the artificial blood vessels showed that 30 days after implantation, more and more uniform pink mucopolysaccharides were observed in the artificial blood vessels seeded with hAMSCs, suggesting that the introduction of hAMSCs makes the artificial blood vessels have better biocompatibility.
[0136] 8.2 Analysis of Fluorescence Staining Results after Abdominal Aorta Transplantation
[0137] In order to further observe the remodeling of artificial blood vessels and explore the effect of hAMSC introduction on vascular remodeling, the present invention performed immunofluorescence staining of multiple regeneration-related proteins on artificial blood vessels 30 days after abdominal aorta implantation.
[0138] 8.2.1 Analysis of EC-related protein expression
[0139] CD31 is expressed in vascular endothelial cells and plays a key role in vascular repair and remodeling. It participates in endothelial cell proliferation, migration, and vascular network formation, and is crucial for cell-cell interactions and network structure formation. vWF is also expressed in endothelial cells and is crucial for blood coagulation, participating in initial hemostasis and thrombosis. VE-Cadherin is an important calcium-dependent cell adhesion molecule that binds to endothelial cells, maintaining vascular stability and tight junctions. It is crucial for vascular integrity and function. Abnormal expression and function of VE-Cadherin are associated with inflammation, tumor angiogenesis, and cardiovascular disease.
[0140] The present invention performed immunofluorescence staining of CD31, vWF, and VE-Cadherin on artificial blood vessels. The results showed that compared with cell-free PLCL artificial blood vessels, hAMSC-PLCL artificial blood vessels expressed more endothelial markers, had more complete endothelial coverage, and CD31-positive cells infiltrated more and deeper into the blood vessel wall. This indicates that the implantation of hAMSCs can improve the endothelialization of artificial blood vessels and the generation of trophic microangiogenesis. Figure 8 shown.
[0141] 8.2.2 Analysis of SMC-related protein expression
[0142] α-SMA is a key marker protein in the early stages of SMC maturation and is involved in SMC contraction. Calponin, a calcium-regulating protein, is involved in both SMC contraction and relaxation and is considered a marker protein for mid-stage SMC maturation. SM-MHC is a key protein in SMCs, closely associated with smooth muscle contraction and a key marker for late-stage, contractile SMC maturation. Contractile SMCs do not express OPN, making OPN a marker for synthetic SMCs.
[0143] The present invention performed immunofluorescence staining of α-SMA, Calponin, SM-MHC, and OPN on PLCL artificial blood vessels and hAMSC-PLCL artificial blood vessels. Figure 9 As shown in the figure, the lumen of the PLCL artificial blood vessels implanted with hAMSCs has more and more continuous α-SMA, Calponin, and SM-MHC than that of the PLCL artificial blood vessels not implanted with hAMSCs. Therefore, the implantation of hAMSCs is beneficial to the regeneration of contractile SMCs in artificial blood vessels.
[0144] In addition, it is worth noting that the hAMSC-seeded PLCL artificial blood vessels also express more OPN, which means that they also have more synthetic SMCs, indicating that hAMSCs promote the generation of both contractile and synthetic SMCs at one month of artificial blood vessel regeneration. Since synthetic SMC and contractile SMC phenotypes can transform into each other, the present inventors speculate that the large number of synthetic SMCs currently present in the hAMSC-PLCL artificial blood vessels will gradually transform into contractile SMCs as the artificial blood vessel remodeling time in vivo is further prolonged. To this end, the present inventors are also conducting artificial blood vessel implantation experiments for longer periods of time.
[0145] 8.2.3 Macrophage-related protein expression analysis
[0146] CD68 is a pan-macrophage marker; CD68-positive cells indicate newly migrated macrophages into the artificial blood vessel. iNOS, an inducible nitric oxide synthase, is primarily expressed on M1 macrophages. CD206 is primarily expressed on M2 macrophages. It is generally believed that M2 macrophages contribute to the constructive remodeling of artificial blood vessels.
[0147] like Figure 10 As shown in the figure, hAMSC-PLCL artificial blood vessels have more green CD68 and CD206 positive macrophages and less iNOS distribution than PLCL artificial blood vessels without hAMSCs, indicating that M2 macrophages actively participate in the reconstruction of artificial blood vessels.
[0148] 8.2.4 Analysis of Extracellular Matrix-Related Protein Expression
[0149] Collagen I and Collagen III play an important role in vascular remodeling. They are the most abundant types of collagen in the vascular wall and are essential for maintaining the structure and function of blood vessels.
[0150] like Figure 11 As shown, hAMSC-PLCL artificial blood vessels have more green Collagen I and Collagen III positive areas than PLCL artificial blood vessels without hAMSC implantation, indicating that hAMSC implantation is beneficial to the regeneration of extracellular matrix of artificial blood vessels.
[0151] 8.2.5 Analysis of Protein Expression Related to Polyester-Specific Degrading Enzymes
[0152] Lipase is a specific degrading enzyme for polyester polymers such as PLCL, which can promote the biodegradation of vascular materials. Figure 12 As shown in the figure, the PLCL artificial blood vessels seeded with hAMSCs have comparable pancreatic lipase and endothelial lipase green fluorescence expression compared to the artificial blood vessels not seeded with hAMSCs, and both are distributed on both sides of the blood vessel wall, indicating that Lipase is involved in the degradation of artificial blood vessels, and hAMSCs have no obvious regulatory effect on this enzyme degradation.
[0153] 8.2.6 Analysis of Matrix Metabolism-Related Protein Expression
[0154] Matrix metabolism enzymes play a crucial role in the remodeling of polylactic acid / polycaprolactone artificial blood vessels. They participate in the biodegradation process of artificial blood vessels, helping them to be gradually replaced by human tissue. MMP2 and MMP9 cleave old extracellular matrix and accelerate its deposition deep within the body, while TIMP1 and TIMP2 inhibit the activity of MMP proteins.
[0155] like Figure 13 As shown in the figure, the PLCL artificial blood vessels seeded with hAMSCs have relatively more MMP2 and MMP9 expression and relatively less TIMP1 and TIMP2 expression than the artificial blood vessels not seeded with hAMSCs, indicating that hAMSCs can regulate the active remodeling of the extracellular matrix.
[0156] 8.2.7 Human Cell Tracking Analysis
[0157] In order to understand the origin of cells during remodeling, the present invention used human-specific nuclear protein NUMA1 to track hAMSCs. Figure 14As shown, the present invention found that at the 30th day, the PLCL artificial blood vessels implanted with hAMSCs still expressed a small amount of green NUMA1 fluorescence, which indicates that at the 30th day, hAMSCs or their derived cells (such as differentiated ECs, SMCs, etc.) in the hAMSC-PLCL artificial blood vessels still existed, and the distribution of hAMSCs and their derived cells was rearranged. Some cells migrated to the outside of the vascular wall, but the overall number was small. This indicates that hAMSCs may be one of the source cells of vascular structural cells, and some hAMSCs can survive in the artificial blood vessels for as long as one month. However, the present invention is still conducting further research on what cell identity the implanted hAMSCs exist in after one month.
[0158] In this example, the present invention mainly evaluates the in vivo performance of hAMSC-PLCL artificial blood vessels. First, by subcutaneously implanting PLCL artificial blood vessels containing and without hAMSCs in rats, the results demonstrated good tissue compatibility between the two, as well as the potential promotion of artificial blood vessel regeneration by loading hAMSCs. Subsequently, a 2-hour acute thrombosis test was performed using a rat abdominal aorta replacement model, demonstrating that hAMSC-PLCL artificial blood vessels indeed have better anti-thrombotic ability than cell-free PLCL artificial blood vessels. Finally, a one-month implantation experiment in the rat abdominal aorta replacement model showed that two cell-free artificial blood vessels were blocked, resulting in the death of the rats, with a patency rate of 60%, while all cell-containing artificial blood vessels were unobstructed, with a patency rate of 100%. This shows that hAMSCs can improve the patency rate of artificial blood vessels.
[0159] Histochemical staining revealed that the cell-containing grafts exhibited greater cell ingrowth and extracellular matrix deposition, resulting in a remodeling degree more similar to that of native vessels, reflecting greater scaffold pore formation and faster degradation. Immunofluorescence staining demonstrated that the cell-containing grafts formed a more complete endothelial cell layer, with more contractile SMCs, more microvessels, and more extracellular matrix production. Despite the superior remodeling effect, expression of the PLCL-specific degrading enzyme Lipase was comparable between the hAMSC-containing and non-hAMSC-containing grafts, suggesting that hAMSC-mediated regulation of this enzyme was not the primary driver of the enhanced graft regeneration.
[0160] In terms of macrophage recruitment, the content of M2 macrophages (CD206) in cell-containing artificial blood vessels is higher than that in cell-free artificial blood vessels. Correspondingly, the content of M1 macrophages (iNOS) in cell-free artificial blood vessels is higher than that in cell-containing artificial blood vessels. This is exactly consistent with the remodeling effects of the two artificial blood vessels. It is speculated that hAMSCs can recruit or polarize more reparative M2 macrophages, which may be one of the important regulatory mechanisms of hAMSCs on the mechanical properties and remodeling effects of artificial blood vessels.
[0161] The basic principles, main features, and advantages of the present invention are shown and described above. Those skilled in the art should understand that the present invention is not limited to the above embodiments. The above embodiments and descriptions are merely illustrative of the principles of the present invention. Various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention. Such changes and modifications are intended to fall within the scope of the present invention. The scope of protection claimed in the present invention is defined by the appended claims and their equivalents.
Claims
1. An artificial blood vessel loaded with human amniotic mesenchymal stem cells, characterized in that: A tubular structure was prepared by electrospinning of polylactic acid-polycaprolactone copolymer PLCL, which had the following characteristics: a fiber diameter of 0.36±0.10 μm, a pore size of 3.63±1.66 μm, a wall thickness of 510±50 μm, an inner diameter of 2.19±0.05 mm, and a porosity of 69.74%±5.81%; and was loaded with human amniotic mesenchymal stem cells hAMSC.
2. The artificial blood vessel loaded with human amniotic mesenchymal stem cells according to claim 1, characterized in that: The human amniotic mesenchymal stem cells hAMSC are extracted and identified through the following steps: mechanical stripping combined with two-enzyme digestion; flow cytometry analysis; Vimentin immunostaining; osteogenic differentiation ability test; adipogenic differentiation ability test.
3. The artificial blood vessel loaded with human amniotic mesenchymal stem cells according to claim 2, characterized in that: The flow cytometry analysis is used to determine the phenotype of hAMSC, including the expression of CD markers; the Vimentin immunostaining is used to verify the mesenchymal characteristics of hAMSC; the osteogenic differentiation ability test includes culturing hAMSC in an osteogenic induction medium containing sodium β-glycerophosphate, vitamin D3 and dehydrocholesterol, and observing the activity of alkaline phosphatase and the formation of mineralized nodules; the adipogenic differentiation ability test includes culturing hAMSC in an adipogenic induction medium containing dexamethasone, insulin, indomethacin and isoproterenol, and observing the formation of oil droplets.
4. The artificial blood vessel loaded with human amniotic mesenchymal stem cells according to claim 2, characterized in that: The extraction and identification also include the determination of cell doubling time and cell survival rate, wherein the cell doubling time is determined by cell counting method, and the cell survival rate is determined by MTT or CCK-8 test.
5. A method for preparing an artificial blood vessel loaded with human amniotic mesenchymal stem cells as claimed in any one of claims 1 to 4, characterized in that The following steps are involved: PLCL is dissolved in a solvent to prepare an electrospinning solution, and the electrospinning solution is processed into a tubular scaffold through an electrospinning device using electrospinning technology; the prepared tubular scaffold is freeze-dried and sterilized with ultraviolet light; human amniotic mesenchymal stem cells hAMSC are evenly loaded into the inner cavity of the tubular scaffold through a rotary implantation technique; and the hAMSC are allowed to adhere to the wall and proliferate in the inner cavity of the tubular scaffold.
6. The method for preparing an artificial blood vessel loaded with human amniotic mesenchymal stem cells according to claim 5, characterized in that: The concentration of the electrospinning solution is 10%, and the voltage used in the electrospinning process is controlled at 12-14 kV.
7. The method for preparing an artificial blood vessel loaded with human amniotic mesenchymal stem cells according to claim 5, characterized in that: The rotational implantation technique comprises the following steps: injecting hAMSC cell suspension into the tubular stent; fixing both ends of the stent with vascular clamps; standing for 2 hours at 37° C. and 5% CO 2 ; flipping the stent 90° every 30 minutes, for a total rotation of 360°.
8. The method for preparing an artificial blood vessel loaded with human amniotic mesenchymal stem cells according to claim 5, characterized in that: The freeze-drying step was performed at -80°C for 24 hours.
9. The method for preparing an artificial blood vessel loaded with human amniotic mesenchymal stem cells according to claim 5, characterized in that: The method of processing the electrospinning liquid into a tubular stent by an electrospinning device comprises the following steps: dissolving PLCL in hexafluoroisopropanol; using a rotating stainless steel rod as a receiving device for electrospinning; and peeling the prepared blood vessel from the stainless steel rod and immersing the blood vessel together with the spinning membrane in deionized water.
10. Use of the artificial blood vessel loaded with human amnion mesenchymal stem cells according to any one of claims 1 to 5 in the preparation of an apparatus for treating cardiovascular diseases, wherein the cardiovascular diseases include coronary artery disease, peripheral artery disease and aortic disease.
